The Hippo effector YAP has recently been identified as a potent driver of
embryonal rhabdomyosarcoma (ERMS). Most reports suggest that the YAP paralogue
TAZ (gene symbol WWTR1) functions as YAP but, in skeletal muscle, TAZ has been
reported to promote myogenic differentiation, whereas YAP inhibits it. Here, we
investigated whether TAZ is also a rhabdomyosarcoma oncogene or whether TAZ acts
as a YAP antagonist. Immunostaining of rhabdomyosarcoma tissue microarrays
revealed that TAZ is significantly associated with poor survival in ERMS. In 12%
of fusion gene-negative rhabdomyosarcomas, the TAZ locus is gained, which is
correlated with increased expression. Constitutively active TAZ S89A
significantly increased proliferation of C2C12 myoblasts and, importantly, colony
formation on soft agar, suggesting transformation. However, TAZ then switches to
enhance myogenic differentiation in C2C12 myoblasts, unlike YAP. Conversely,
lentiviral shRNA-mediated TAZ knockdown in human ERMS cells reduced proliferation
and anchorage-independent growth. While TAZ S89A or YAP1 S127A similarly
activated the 8XGTIIC-Luc Hippo reporter, only YAP1 S127A activated the Brachyury
(T-box) reporter. Consistent with its oncogene function, TAZ S89A induced
expression of the ERMS cancer stem cell gene Myf5 and the serine biosynthesis
pathway (Phgdh, Psat1, Psph) in C2C12 myoblasts. Thus, TAZ is associated with
poor survival in ERMS and could act as an oncogene in rhabdomyosarcoma.
«
The Hippo effector YAP has recently been identified as a potent driver of
embryonal rhabdomyosarcoma (ERMS). Most reports suggest that the YAP paralogue
TAZ (gene symbol WWTR1) functions as YAP but, in skeletal muscle, TAZ has been
reported to promote myogenic differentiation, whereas YAP inhibits it. Here, we
investigated whether TAZ is also a rhabdomyosarcoma oncogene or whether TAZ acts
as a YAP antagonist. Immunostaining of rhabdomyosarcoma tissue microarrays
revealed that TAZ is sign...
»